LiquidSEQ™ with Reflex to Solid TumorSEQ™
*Build Your Own Panel Eligible [?]
|
$8155
|
|
|
Description:
Plasma-based ctDNA tumor profiling with reflex to tissue-based tumor profiling may be clinically useful in specific circumstances such as when expedited biomarker testing is needed to inform patient care or when tissue adequacy or availability may be limited.The 523-gene comprehensive genomic profiling panel is intended to help oncologists deliver precision medicine by providing personalized genomic analysis of a patient's tumor. This comprehensive panel offers the opportunity for a broader scope of genomic information compared to single gene tests or smaller panels. For example, it may be useful for patients with limited or ill-defined treatment options and for those considering clinical trials. The test is designed to detect single nucleotide variants (SNVs) and small insertions/deletions, as well as whole-gene copy number alterations and translocations in a select group of genes. Microsatellite instability (MSI) and tumor mutation burden (TMB) are also evaluated.
Categories:
Price:
$8155
|
|
Lithium
*Build Your Own Panel Eligible [?]
|
$115
|
|
|
Description:
Lithium is used to treat manic-depressive disorders and the manic phase of affective disorders, including mania. The therapeutic window is relatively small. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity.
Patient Instructions:
Collect just prior to next dose.
Categories:
Price:
$115
|
|
Lithium, RBCs
*Build Your Own Panel Eligible [?]
|
$300
|
|
Description:
- Monitor lithium medication levels closely
- Check your dosage effectiveness regularly
- Track therapy stability over time
Categories:
Price:
$300
|
|
Liver Fibrosis, Fibrosis-4 (FIB-4) Index Panel
*Build Your Own Panel Eligible [?]
|
$49
|
|
|
Description:
The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4).
Categories:
Price:
$49
|
|
Liver Fibrosis, FibroTest-ActiTest Panel
*Build Your Own Panel Eligible [?]
|
$610
|
|
|
Description:
FibroTest and ActiTest permit the non-invasive evaluation of Hepatitis C (or B) individuals for the presence of liver fibrosis and liver inflammation, respectively. The FibroTest and ActiTest scores are calculated based on patient age, gender and concentrations of serum of y-glutamyl transferase (GGT), total bilirubin (TB), a-2 macroglobulin, haptoglobin, apolipoprotein A1 and alanine aminotransferase (ActiTest). Fibrotest and ActiTest Scores, on a scale of 0.0 to 1.0, are assigned a Metavir scale indicating the level of fibrosis or inflammation present.
Categories:
Price:
$610
|
|
Liver Fibrosis, Hepatic Function Panel with Fibrosis-4 (FIB-4) Index
*Build Your Own Panel Eligible [?]
|
$49
|
|
|
Description:
The FIB-4 index is a simple non-invasive approach using selected laboratory measures (AST, ALT, platelet count) in combination with patient age to assess if an individual is at higher risk for advanced liver fibrosis (F3-F4).
Categories:
Price:
$49
|
|
Liver Function Profile
*Build Your Own Panel Eligible [?]
|
$57
|
|
|
Description:
The Liver Function Profile (Hepatic Function Panel) is a comprehensive panel that assesses functional health of the liver. Abnormal results may indicate liver damage or hepatitis infection.
Significant deviations from the normal range may require further evaluation by your physician.
Alternative Names(s):
Hepatic Function Panel (7)
Includes:
Alanine aminotransferase (ALT/SGPT); albumin, serum; alkaline phosphatase, serum; aspartate aminotransferase (AST/SGOT); bilirubin, direct; bilirubin, total; protein, total, serum
Categories:
Liver diseases,
Price:
$57
|
|
Liver Monitoring Blood Scan
|
$149
|
|
Description:
- Reveal liver health issues effortlessly
- Detect potential liver damage early
- Highlight areas needing lifestyle changes
Includes:
Comprehensive Metabolic Profile ( includes eGFR ): Albumin, Albumin/Globulin Ratio (calculated), Alkaline Phosphatase, ALT, AST, BUN/Creatinine Ratio (calculated), Calcium, Carbon Dioxide, Chloride, Creatinine with GFR Estimated, Globulin (calculated), Glucose, Potassium, Sodium, Total Bilirubin, Total Protein, Urea Nitrogen Alpha-Fetoprotein (AFP), Serum Complete Blood Count / CBC (includes Differential and Platelets): WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils) Gamma Glutamyl Transpeptidase (GGT)
Patient Instructions:
You should fast for 12 hours before collection of the specimen. Fasting is defined as no consumption of food or beverage other than water for at least 12 hours before testing. Estimated turnaround for results is 4 business days. If confirmation testing is required, the estimated time may be extended.
Categories:
Cancer detection,
Price:
$149
|
|
Lobster (f80) IgE
*Build Your Own Panel Eligible [?]
|
$49
|
|
|
Description:
This test detects the presence of specific IgE against lobster. A positive test only indicates that a person is sensitized and potentially allergic to this allergen. A diagnosis of allergy requires clinical signs and symptoms that appear to be associated with exposure to the allergen in addition to the detection of markers of IgE sensitization [1].More specific information about this allergen can be found on the following website: https://www.thermofisher.com/phadia/us/en/resources/allergen-encyclopedia.htmlReference1. Bernstein IL, et al. Ann Allergy Asthma Immunol. 2008;100(3 Suppl 3):S1-S148.
Categories:
Price:
$49
|
|
Lobster, Spiny (f304) IgE
*Build Your Own Panel Eligible [?]
|
$49
|
|
|
Description:
This test detects the presence of specific IgE against spiny lobster. A positive test only indicates that a person is sensitized and potentially allergic to this allergen. A diagnosis of allergy requires clinical signs and symptoms that appear to be associated with exposure to the allergen in addition to the detection of markers of IgE sensitization [1].More specific information about this allergen can be found on the following website: https://www.thermofisher.com/phadia/us/en/resources/allergen-encyclopedia.htmlReference1. Bernstein IL, et al. Ann Allergy Asthma Immunol. 2008;100(3 Suppl 3):S1-S148.
Categories:
Price:
$49
|
|
Long Chain Acyl-CoA Dehydrogenase (LCHAD) Mutation Analysis
*Build Your Own Panel Eligible [?]
|
$726
|
|
|
Description:
Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency is an autosomal recessive inborn error of fatty acid metabolism that can cause recurrent episodes of hypoglycemia and metabolic decompensation. Studies have suggested that a percentage of patients with sudden infant death syndrome (SIDS) actually had undiagnosed LCHAD deficiency. Almost all patients with LCHAD deficiency are homozygous for a G>C transition at nucleotide position 1528 in the LCHAD gene.
Categories:
Price:
$726
|
|
Lp-PLA2 Activity(6)
*Build Your Own Panel Eligible [?]
|
$153
|
|
|
Description:
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor Acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, Lp-PLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies. The activity assay is an enzyme assay run on an automated chemistry platform.
Alternative names: PAF-AH
Patient Instructions:
Fasting is preferred, but not required
Categories:
Heart & cholesterol,
Price:
$153
|
|
LRP4 Autoantibody Test
*Build Your Own Panel Eligible [?]
|
$1428
|
|
|
Description:
Detects anti-LRP4 (low density lipoprotein receptor-related protein 4) in the sera of patients with Myasthenia Gravis (MG). The LRP4 protein activates MuSK kinase activity and promotes the clustering of AChR and their stabilization at the NMJ. Anti-LRP4 antibodies are found in approximately 9.2% (range 2% to 50%) of MG patients who are negative for both anti-AChR and anti-MuSK.
Categories:
Price:
$1428
|
|
Lung Cancer Blood Scan
|
$82
|
|
Description:
- Detect early signs of lung cancer
- Unveil hidden lung health issues
- Confirm your lung health status
Includes:
Complete Blood Count / CBC (includes Differential and Platelets): WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils) Comprehensive Metabolic Profile ( includes eGFR ): Albumin, Albumin/Globulin Ratio (calculated), Alkaline Phosphatase, ALT, AST, BUN/Creatinine Ratio (calculated), Calcium, Carbon Dioxide, Chloride, Creatinine with GFR Estimated, Globulin (calculated), Glucose, Potassium, Sodium, Total Bilirubin, Total Protein, Urea Nitrogen Carcinoembryonic Antigen (CEA)
Patient Instructions:
You should fast for 12 hours before collection of the specimen. Fasting is defined as no consumption of food or beverage other than water for at least 12 hours before testing. Estimated turnaround for results is 3 business days. If confirmation testing is required, the estimated time may be extended.
Categories:
Cancer detection,
Price:
$82
|
|
Lung Cancer Mutation Panel (EGFR, KRAS, ALK)
*Build Your Own Panel Eligible [?]
|
$2898
|
|
|
Description:
This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors, whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Categories:
Price:
$2898
|
|
Lung Cancer (NSCLC), ROS1 (6q22) Rearrangement, FISH
*Build Your Own Panel Eligible [?]
|
$968
|
|
|
Description:
ROS1 rearrangement has been identified in 1.7% of non small-cell lung cancer (NSCLC) by using a FISH assay. Treatment with ALK/MET tyrosine kinase inhibitors such as crizotinib (Xalkori(R)) has shown early evidence of therapeutic efficacy in ROS1-rearranged NSCLC (Bergethon, et al. J Clin Oncol. 2012;30:863-870)
Categories:
Price:
$968
|
|
Lung Hemorrhage and Nephritis Panel
*Build Your Own Panel Eligible [?]
|
$621
|
|
|
Description:
To help with diagnosis of Goodpasture's Syndrome or vascular diseases such as crescentic glomerulonephritis, Wegener's granulomatosis, or microscopic polyarteritis.
Categories:
Price:
$621
|
|
LungSEQ Concurrent Panel, without PD-L1
*Build Your Own Panel Eligible [?]
|
$7095
|
|
|
Description:
This test is intended to be used for the mutational profiling of tumors from patients with Non-Small-Cell Lung Cancer in order to help prioritize and direct treatment. It may be useful for patients who have become refractory to prior therapies and are searching for investigational targeted therapies offered in clinical trials or for newly diagnosed patients who would like to know their mutational profile to inform treatment options with approved targeted therapies or for the identification of potential future clinical trials or future approvals of targeted therapies.
Categories:
Price:
$7095
|
|
LUNGSEQ Panel
*Build Your Own Panel Eligible [?]
|
$2213
|
|
|
Description:
This test is intended to be used for the molecular genotyping of tumors from patients with Non-Small-Cell Lung Cancer in order to help prioritize treatment.
Categories:
Price:
$2213
|
|
Lupine Seed (f335) IgE
*Build Your Own Panel Eligible [?]
|
$49
|
|
|
Description:
This test detects the presence of specific IgE against lupine seeds. A positive test only indicates that a person is sensitized and potentially allergic to this allergen. A diagnosis of allergy requires clinical signs and symptoms that appear to be associated with exposure to the allergen in addition to the detection of markers of IgE sensitization [1].More specific information about this allergen can be found on the following website: https://www.thermofisher.com/phadia/us/en/resources/allergen-encyclopedia.htmlReference1. Bernstein IL, et al. Ann Allergy Asthma Immunol. 2008;100(3 Suppl 3):S1-S148.
Categories:
Price:
$49
|
|
Lupus Anticoagulant and Antiphospholipid Confirmation (non-Coumadin) with Consultation
*Build Your Own Panel Eligible [?]
|
$676
|
|
Description:
- Screen for unexplained blood clot risk
- Check antibodies linked to miscarriage risk
- Monitor autoimmune clotting antibody levels
Categories:
Price:
$676
|
|
Lupus Anticoagulant and Antiphospholipid Confirmation (on Coumadin®)
*Build Your Own Panel Eligible [?]
|
$806
|
|
Description:
- Screen for autoimmune clotting risk
- Confirm antibody results while on Coumadin
- Monitor unexplained clot or miscarriage history
Categories:
Price:
$806
|
|
Lupus Anticoagulant and Antiphospholipid Confirmation (on Coumadin®) with Consultation
*Build Your Own Panel Eligible [?]
|
$806
|
|
Description:
- Check blood clot risk factors
- Screen antibody-related clotting problems
- Monitor clotting risk while medicated
Categories:
Price:
$806
|
|
Lupus Anticoagulant Evaluation with Reflex
*Build Your Own Panel Eligible [?]
|
$253
|
|
Description:
- Checks for blood clotting issues
- Detects immune system blood problems
- Identifies lupus-related clotting risks
Includes:
Lupus Anticoagulant Evaluation with Reflex
Categories:
Price:
$253
|
|
Lupus Panel 2 with ANA, IFA with Reflex to Titer and Pattern
*Build Your Own Panel Eligible [?]
|
$578
|
|
|
Description:
This panel supports the evaluation of systemic lupus erythematosus (SLE) and related autoimmune diseases, such as mixed connective tissue disease, systemic sclerosis, and Sjogren syndrome. However, testing for subserologies in the absence of a positive antinuclear antibody (ANA) result and clinically suspected autoimmune disease is generally not recommended [1].This panel simultaneously tests for ANAs with an immunofluorescence assay (IFA) and 6 specific autoantibodies associated rheumatic and related diseases. The ANA testing has high sensitivity (97%) for SLE but limited specificity (34%) [2]. Thus, a positive ANA test result does not exclude other autoimmune diseases with similar clinical features [3]. Testing for specific autoantibodies, as well as other biomarkers associated with these autoimmune diseases, in a panel may expedite the evaluation of SLE.Although individuals with negative results on the ANA IFA usually also have negative results for specific ANAs, Jo-1 antibody may be detected in ANA IFA-negative patients with some types of myositis, and SSA antibody may be detected in some ANA IFA-negative patients with lupus or Sjogren syndrome [1].The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Yazdany J, et al. Arthritis Care Res (Hoboken). 2013;65(3):329-339.2. Petri M, et al. Arthritis Rheum. 2012;64(8):2677-2686.3. Kavanaugh A, et al. Arch Pathol Lab Med. 2000;124(1):71-81.
Categories:
Price:
$578
|
|
Lupus Panel 3 with ANA, IFA with Reflex to Titer and Pattern
*Build Your Own Panel Eligible [?]
|
$1631
|
|
Description:
- Checks for lupus-related antibodies
- Identifies autoimmune disease indicators
- Analyzes blood for lupus markers
Includes:
ANA Screen, IFA, with Reflex to Titer and Pattern DNA (ds) Antibody Sjogren's Antibodies (SS-A, SS-B) Sm Antibody RNP Antibody Chromatin (Nucleosomal) Antibody Complement Component C3c and C4c Complement, Total (CH50)
Categories:
Price:
$1631
|
|
Lupus Panel 4 with ANA, IFA with Reflex to Titer and Pattern
*Build Your Own Panel Eligible [?]
|
$1327
|
|
|
Description:
This panel can be helpful in the diagnosis of systemic lupus erythematosus (SLE) and several other autoimmune diseases, including mixed connective tissue disease, Sjogren syndrome, systemic sclerosis, and autoimmune thyroid disease. The panel simultaneously tests for antinuclear antibodies (ANAs) with an immunofluorescence assay (IFA), performed on human epithelial type 2 (HEp-2) cells, and 11 biomarkers associated with these conditions. For specimens with positive ANA IFA results, reflex testing for ANA titer and pattern is performed.The ANA testing has high sensitivity (97%) for SLE but limited specificity (34%) [1]. Thus, a positive ANA test does not exclude other autoimmune diseases with similar clinical features [2]. Testing for specific antibodies in a panel may expedite the evaluation of SLE but is generally not recommended [3].The results of this test should be interpreted in the context of pertinent clinical and family history and physical examination findings.References1. Petri M, et al. Arthritis Rheum. 2012;64(8):2677-2686.2. Kavanaugh A, et al. Arch Pathol Lab Med. 2000;124(1):71-81.3. Yazdany J, et al. Arthritis Care Res (Hoboken). 2013;65(3):329-339.
Categories:
Price:
$1327
|
|
Lupus Screening Panel
|
$229
|
|
Description:
- Pinpoint the cause of your joint pain
- Reveal hidden inflammation affecting your health
- Clarify unexplained fatigue and skin issues
Includes:
C-Reactive Protein (CRP), High Sensitivity (Cardiac Risk Assessment) Comprehensive Metabolic Profile ( includes eGFR ): Albumin, Albumin/Globulin Ratio (calculated), Alkaline Phosphatase, ALT, AST, BUN/Creatinine Ratio (calculated), Calcium, Carbon Dioxide, Chloride, Creatinine with GFR Estimated, Globulin (calculated), Glucose, Potassium, Sodium, Total Bilirubin, Total Protein, Urea Nitrogen ANA Screen IFA w/ Ref to Titer and Pattern Rheumatoid Factor (RA) PT and PTT Complete Blood Count / CBC (includes Differential and Platelets): WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils) Sedimentation Rate, Modified Westergren DNA (ds) Antibody
Patient Instructions:
You should fast for 12 hours before collection of the specimen. Fasting is defined as no consumption of food or beverage other than water for at least 12 hours before testing. Estimated turnaround for results is 4 business days. If confirmation testing is required, the estimated time may be extended.
Categories:
Autoimmune diseases,
Price:
$229
|
|
Lurasidone, Serum/Plasma
*Build Your Own Panel Eligible [?]
|
$430
|
|
|
Description:
Therapeutic drug monitoring.
Categories:
Price:
$430
|
|
Luteinizing Hormone (LH)
*Build Your Own Panel Eligible [?]
|
$53
|
|
|
Description:
The Luteinizing Hormone (LH) test is routinely ordered to evaluate fertility in both men and women. LH can also assist in the diagnosis of pituitary gland disorders and menstrual irregularities. This test is useful in the differential diagnosis of pituitary and gonadal insufficiency and in children with precocious puberty.
A significant deviation from the normal range may require further evaluation by your physician.
Alternative Name(s): Leuteinizing Hormone, Luteinizing Hormone (LH), Interstitial Cell Stimulating Hormone
Includes:
Luteinizing Hormone (LH), Serum.
Categories:
Hormones & metabolism,
Specific blood tests for women,
Infertility blood testing,
Price:
$53
|
|
Lyme Disease Antibodies (IgG, IgM), Immunoblot
*Build Your Own Panel Eligible [?]
|
$137
|
|
Description:
- Detects Lyme disease antibodies
- Checks immune response to Lyme
- Identifies Lyme infection stage
Categories:
Price:
$137
|
|
Lyme Disease, Antibodies (IgG, IgM), Immunoblot
*Build Your Own Panel Eligible [?]
|
$86
|
|
|
Description:
Lyme disease is transmitted by a tick vector carrying Borrelia burgdorferi. Immunoblot testing qualitatively examines, with high specificity, antibodies in a patient's specimen. Immunoblot testing is appropriate for confirming a detected screening test result.
The CDC currently recommends a two-step process when testing blood for evidence of antibodies against the Lyme disease bacteria. Both steps can be done using the same blood sample.
The first step uses a screening procedure. If this first step is negative, no further testing of the specimen is recommended. If the first step is positive or indeterminate (sometimes called "equivocal"), the second step should be performed. The second step uses a test called an immunoblot test. Results are considered positive only if the screening and the immunoblot are both positive.
The two steps of Lyme disease testing are designed to be done together. CDC does not recommend skipping the first test and just doing the Immunoblot. Doing so will increase the frequency of false positive results and may lead to misdiagnosis and improper treatment.
A significant deviation from the normal range may require further evaluation by your physician.
Alternative Name(s): Borrelia burgdorferi
Includes:
Lyme Disease, Antibodies (IgG, IgM), Immunoblot This test does NOT include the screening test.
Patient Instructions:
Estimated turnaround for results is 7 business days. If confirmation testing is required, the estimated time may be extended.
Categories:
Infectious diseases,
Price:
$86
|
|
Lyme Disease Antibody (IgG), Immunoblot
*Build Your Own Panel Eligible [?]
|
$309
|
|
|
Description:
Lyme disease is caused by a tick vector carrying borrelia burgdorferi. Immunoblot testing qualitatively examines with high specificity antibodies in a patient's specimen. Immunoblot testing is appropriate for confirming a detected EIA or IFA test result.
Categories:
Price:
$309
|
|
Lyme Disease Antibody Index for CNS Infection
*Build Your Own Panel Eligible [?]
|
$1150
|
|
|
Description:
The Lyme disease antibody index is used as an aid for diagnosing neuroborreliosis. The assay requires paired serum and CSF. A result set of lyme disease antibody index >1.2, control antibody index <1.0, and albumin ratio <0.0078 provides strong evidence of intrathecal synthesis of b. Burgdorferi antibodies and supports the diagnosis of neuroborreliosis.
Categories:
Price:
$1150
|
|
Lyme Disease Antibody with Reflex to Antibodies IGG & IGM Blot
*Build Your Own Panel Eligible [?]
|
$106
|
|
|
Description:
Lyme disease is caused by a bacterium borrelia burgdorferi and is transmitted by ticks. The screening test is high sensitivity for antibody detection. Immunoblot testing qualitatively examines with high specificity antibodies in a patient's specimen. Immunoblot testing is appropriate for confirming a detected screening result. Lyme Disease Antibodies (IgG, IgM) Immunoblot Confirmation is ONLY performed when the Lyme Disease Antibody screening is positive.
Aids in the diagnosis of acute or chronic infection with the lyme disease agent.
Lyme disease is an infection caused by the bite of an infected tick. The disease often begins as a rash. If you don't get treatment, the infection can cause serious nerve or heart problems as well as a disabling type of arthritis (pain and swelling in one or more joints caused by inflammation).
Combination of IgM and IgM/IgG testing has the potential to provide the earliest and the broadest time window for serological detection. Immunoblot confirmation is recommended for positive results and is ONLY performed when the Lyme Disease Antibody screening is positive.
The CDC currently recommends a two-step process when testing blood for evidence of antibodies against the Lyme disease bacteria. Both steps can be done using the same blood sample.
The first step uses a screening procedure. If this first step is negative, no further testing of the specimen is recommended. If the first step is positive or indeterminate (sometimes called "equivocal"), the second step should be performed. The second step uses a test called an immunoblot test. Results are considered positive only if the screening and the immunoblot are both positive.
The two steps of Lyme disease testing are designed to be done together. CDC does not recommend skipping the first test and just doing the Immunoblot. Doing so will increase the frequency of false positive results and may lead to misdiagnosis and improper treatment.
If the screening test is negative, the Immunoblot will not be performed and you will not receive the bands with your results.
A significant deviation from the normal range may require further evaluation by your physician.
Includes:
Lyme Disease Antibody, screening with Reflex to Antibodies IGG & IGM Immunoblot
Lyme Disease Antibodies (IgG, IgM) Immunoblot Confirmation is ONLY performed when the Lyme Disease Antibody screening is positive.
Note: Confirmation testing is performed on reactive results only if initial values fall within a designated range requiring additional confirmation.
Categories:
Infectious diseases,
Price:
$106
|
|
Lyme Disease Antibody with Reflex to Immunoassay (IgG, IgM) (MTTT)
*Build Your Own Panel Eligible [?]
|
$73
|
|
|
Description:
This test is for the qualitative detection of antibodies against Borrelia burgdorferi, the causative agent of Lyme disease, using the modified two-tier testing (MTTT) algorithm. Initial testing is performed using a Lyme total (IgG and IgM) antibody assay and if positive or equivocal, the sample is then tested using separate IgG and IgM immunoassays. This algorithm differs from the STTT algorithm in that the second-tier assays are chemiluminescent immunoassays, not immunoblots. MTTT may be able to assist in the identification of Lyme disease with improved sensitivity earlier in infection compared to STTT.Diagnostic testing for Lyme disease relies on a two-step algorithm to increase sensitivity and specificity. Testing is performed in patients presenting with signs and symptoms consistent with Lyme disease and with potential tick exposure in endemic regions. Most infections are transmitted by blacklegged ticks in the upper midwestern, northeastern, and mid-Atlantic states.Negative results can occur in patient with recent infection (≤14 days). In persons with recent or past infection, both IgG and IgM can be detectable months to years after the infection has resolved. Therefore, it is recommended to interpret results in the context of the clinical picture, history, including exposure risk, and symptom onset.References:1. Mead, P. et al. Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease. Wkly Rep. 2019 Aug 16;68(32):703. doi: 10.15585/mmwr.mm6832a4.2. Suggested Reporting Language, Interpretation and Guidance For Lyme Disease Serologic Test Results. Association of Public Health Laboratories. April 2024.3. Sfeir MM, Meece JK, Theel ES, et al. Multicenter clinical evaluation of modified two-tiered testing algorithms for Lyme disease using zeus scientific commercial assays. J Clin Microbiol 2022; 60:e0252821.4. Tickborne Diseases of the United States. A Reference Manual for Healthcare Providers, Sixth Edition, 2022. Centers for Disease Control and Prevention.
Categories:
Price:
$73
|
|
Lymphocyte Clonality Panel, PCR
*Build Your Own Panel Eligible [?]
|
$2623
|
|
|
Description:
This assay interrogates simultaneously the immunoglobulin kappa (IGK), the immunoglobulin heavy chain (IGH), the T-cell receptor beta (TCRB) and the T-cell receptor gamma (TCRG) genes by PCR methods based on the BIOMED-2 consensus. This combination assay will be most useful in diagnosing mixed B-cell and T-cell atypical infiltrates and for lineage identification in poorly differentiated or immature lymphoid malignancies.
Categories:
Price:
$2623
|
|
Lymphocyte Subset Panel 1
*Build Your Own Panel Eligible [?]
|
$818
|
|
|
Description:
Immunophenotypic analysis may assist in evaluating cellular immunocompetency in suspected cases of primary and secondary immunodeficiency states.
Categories:
Price:
$818
|
|
Lymphocyte Subset Panel 2
*Build Your Own Panel Eligible [?]
|
$716
|
|
|
Description:
T-lymphocyte count assists in evaluating cellular immunocompetency.
Categories:
Price:
$716
|
|
Lymphocyte Subset Panel 3
*Build Your Own Panel Eligible [?]
|
$726
|
|
|
Description:
T-lymphocyte count assists in evaluating cellular immunocompetency.
Categories:
Price:
$726
|
|
Lymphocyte Subset Panel 4 (CD4:CD8 Ratio Profile)
*Build Your Own Panel Eligible [?]
|
$206
|
|
|
Description:
Assists in evaluating helper and suppressor cell immune status in immunodeficiency diseases such as AIDS. HIV-1 infection results in a decrease of CD4 T cells, an increase of CD8 T cells, a decrease in the CD4:CD8 ratio, and a progressive destruction of immune function. In HIV-1 seropositive patients, enumeration of CD4 T cells may be used for prognostic purposes and to monitor disease progression and antiretroviral therapy.
Significant deviations from the normal range may require further evaluation by your physician.
Includes:
Absolute Lymphocytes, Percentage CD4, Absolute CD4, Percentage CD8, Absolute CD8, CD4/CD8 Ratio (calculated)
Categories:
Infectious diseases,
Price:
$206
|
|
Lymphogranuloma Venereum (LGV) Differentiation Antibody Panel, MIF
*Build Your Own Panel Eligible [?]
|
$531
|
|
|
Description:
Lymphogranuloma venerum (LGV) is a clinical syndrome caused by infection with C. trachomatis which typically includes genital bubonic disease. The serologic detection of C. trachomatis infection is complicated by the presence of crossreactive antibody to other Chlamydia species or nonspecific stimulation of anti-Chlamydia Ab. To differentiate C. trachomatis infection from other Chlamydia species, a panel of Chlamydia is tested for the determination of specific antibody titers.
Categories:
Price:
$531
|
|
Lynch Syndrome, MLH1 Sequencing and Deletion/Duplication
*Build Your Own Panel Eligible [?]
|
$1348
|
|
|
Description:
Sequencing: This test should be offered to patients with colorectal cancer who meet the Bethesda criteria established by the National Cancer Institute (NCI), and/or that their tumors display microsatellite instability (MSI) or replication error (RER) phenotype. Detection of a germline mutation in one or the mismatch repair genes helps to establish a clinical diagnosis of HNPCC in affected patients. Mutation detection in at risk family member allows predictive diagnosis of the disease and thus intensive screening and early intervention of cancer. Deletion/Duplication: This assay detects deletions and/or duplication involving one or more exons, as well as the entire MLH1 gene. This assay cannot detect smaller genetic alterations, such as point mutations affecting amino acid coding or mRNA splicing. The assay cannot detect mutations affecting MLH1 gene regions not examined in the assay (including most of the intronic regions). This assay cannot rule out the presence of germline mutations involving other mismatch repair genes.
Categories:
Price:
$1348
|
|
Lynch Syndrome, MSH2 Sequencing and Deletion/Duplication (Including EPCAM)
*Build Your Own Panel Eligible [?]
|
$1348
|
|
|
Description:
Sequencing: This test should be offered to patients with colorectal cancer who meet the Bethesda criteria established by the National Cancer Institute (NCI), and/or that their tumors display microsatellite instability (MSI) or replication error (RER) phenotype. Detection of a germline mutation in one of the mismatch repair genes helps to establish a clinical diagnosis of HNPCC in affected patients. Mutation detection in at risk family member allows predictive diagnosis of the disease and thus intensive screening and early intervention of cancer. Deletion/Duplication: This assay detects deletions and/or duplication involving one or more exons for the MSH2 gene, and exons 8 and 9 for the EPCAM gene. This assay cannot detect smaller genetic alterations, such as point mutations affecting amino acid coding or mRNA splicing. This assay cannot detect mutations affecting MSH2 and EPCAM gene regions not examined in the assay (including most of the intronic regions). This assay cannot rule out the presence of germline mutations involving other mismatch repair genes.
Categories:
Price:
$1348
|
|
Lynch Syndrome, MSH6 Sequencing and Deletion/Duplication
*Build Your Own Panel Eligible [?]
|
$1348
|
|
|
Description:
Sequencing: This test should be offered to patients with colorectal cancer who meet the Bethesda criteria established by the National Cancer Institute (NCI), and/or that their tumors display microsatellite instability (MSI) or replication error (RER) phenotype. Detection of a germline mutation in one of the mismatch repair genes helps to establish a clinical diagnosis of HNPCC in affected patients. Mutation detection in at risk family member allows predictive diagnosis of the disease and thus intensive screening and early intervention of cancer. Deletion/Duplication: This assay detects deletion and/or duplication involving one or more exons, as well as the entire MSH6 gene. This assay cannot detect smaller alterations, such as point mutations affecting amino acid coding or mRNA splicing. The assay cannot detect mutations affecting gene regions not examined in the assay (including most of the intronic regions). This assay cannot rule out the presence of germline mutations involving other mismatch repair genes.
Categories:
Price:
$1348
|
|
Lynch Syndrome Panel
*Build Your Own Panel Eligible [?]
|
$4264
|
|
Description:
- Checks genetic risk for colon cancer
- Identifies inherited cancer-causing genes
- Detects genetic mutations linked to cancer
Includes:
Lynch Syndrome Panel
Categories:
Price:
$4264
|
|
Lynch Syndrome, PMS2 Sequencing and Deletion/Duplication
*Build Your Own Panel Eligible [?]
|
$1348
|
|
|
Description:
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant genetic disorder characterized by the familial accumulation of early onset colorectal, endometrial and other tumors, and accounts for approximately 3-5% of all colon cancer cases. HNPCC is caused by germline mutations in four genes involved in the DNA mismatch repair pathway: MLH1, MSH2, MSH6, and PMS2. MLH1 and MSH2 mutations account for approximately 90% of HNPCC cases, MSH6 accounts for approximately 7-10%, while PMS2 accounts for less than 5%. The prevalence of PMS2 mutations is not well established but some studies have shown that large deletions account for approximately 21-37% of PMS2 mutations. The prevalence of sequence variants is not well established.
Categories:
Price:
$1348
|
|
Lynch Syndrome Tumor Panel, IHC with Interpretation
*Build Your Own Panel Eligible [?]
|
$1325
|
|
|
Description:
Genetic defects in these four mismatch repair proteins underlie most cases of Lynch syndrome or hereditary non-polyposis colorectal carcinoma (HNPCC). This IHC panel looks for loss of expression of one or more of these proteins in cases of suspected HNPCC in tumor tissues from colorectal carcinomas, endometrial carcinomas, sebaceous adenoma/carcinoma or other adnexal tumors. If IHC results are abnormal, guidance is provided in the report on the recommended next step in the workup.
Categories:
Price:
$1325
|
|
Lynch Syndrome Tumor Panel, IHC without Interpretation
*Build Your Own Panel Eligible [?]
|
$1040
|
|
|
Description:
Genetic defects in these four mismatch repair proteins underlie most cases of Lynch syndrome or hereditary non-polyposis colorectal carcinoma (HNPCC). This IHC panel looks for loss of expression of one or more of these proteins in cases of suspected HNPCC in tumor tissues from colorectal carcinomas, endometrial carcinomas, sebaceous adenoma/carcinoma or other adnexal tumors. If IHC results are abnormal, guidance is provided in the report on the recommended next step in the workup.
Categories:
Price:
$1040
|
|
Lysosomal Acid Lipase Activity, Blood
*Build Your Own Panel Eligible [?]
|
$612
|
|
|
Description:
Lysosomal acid lipase deficiency (LAL-D) is a lipid storage disorder with two clinically distinct phenotypes, Wolman disease (WD) and cholesteryl ester storage disease (CESD). Both phenotypes follow an autosomal recessive inheritance pattern and are caused by mutation in the LIPA gene.WD, the early onset phenotype of LAL deficiency, is characterized by vomiting, diarrhea, failure to thrive, abdominal distension, and hepatosplenomegaly. Peripheral blood lymphocytes are vacuolated and foam cells are present in the bone marrow. Approximately 50% of infants have adrenal calcifications. WD typically presents in the first weeks of life and is fatal in infancy.CESD, the late onset phenotype of LAL deficiency, is clinically variable with patients presenting at any age with progressive hepatomegaly and often splenomegaly, leading to microvesicular steatosis and often liver failure. CESD is likely underdiagnosed and frequently diagnosed incidentally after liver pathology reveals findings similar to non- alcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).The LAL-D test is used to evaluate patients with a clinical presentation suggestive of lysosomal acid lipase deficiency and support a diagnosis of disease.
Categories:
Price:
$612
|
